RxDoctor Payments Data

Jennifer Eckerman

Physician Assistant · Templeton, CANPI 1790876381

Payments from drug & device makers

$6,416in general payments, 2019–2025

Across 242 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$592
  • AbbVie$371
  • Johnson & Johnson$359
  • Pfizer$319
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$80112%
  • Food & beverage$5,22181%
  • Education$3946%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,416 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$226,608
Medicare patients
779
Services billed
15,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron286$281,156
GemtesaVibegron190$199,640
Abiraterone Acetate20$61,653
Methenamine Hippurate155$17,268
Mirabegron ErMirabegron17$14,658
TestimTestosterone16$9,196
Estradiol83$7,787
Tamsulosin Hcl430$7,607
Finasteride371$6,834
Trospium Chloride ErTrospium Chloride22$5,400
Silodosin56$4,987
Dutasteride109$4,497
Alfuzosin Hcl ErAlfuzosin Hcl176$4,228
Tadalafil51$3,531
Potassium Citrate ErPotassium Citrate45$3,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,258$281,156286 claims
Sumitomo Pharma America, Inc.Gemtesa$592$199,640190 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$48$61,65320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Templeton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →